stockrowCreative Medical Technology Holdings, Inc.
CELZ Healthcare Biotechnology
Creative Medical Technology Holdings, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $6,000.00, down 45.5% from fiscal 2024.
- Revenue
- 0.00%
- EPS
- +14.6%
- Free cash flow
- −27.1%
Quarter to June 2026, against a year earlier
Follow CELZ
Alert me
Creative Medical Technology Holdings, Inc. (CELZ) EV/Sales
As of 6 November 2026, Creative Medical Technology Holdings, Inc. (CELZ) trades at a EV/Sales of −378×. Over the past ten years it has ranged from −380× (November 2026) to 548,273× (October 2019); the current reading is higher than 0% of that period. That is below the Biotechnology industry median of 9.0× and below the Healthcare sector median of 3.6×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2025 | −142× | — |
| FY2024 | −120× | — |
| FY2023 | −41.1× | — |
| FY2022 | −26.4× | — |
| FY2021 | −46.0× | — |
| FY2020 | 53.1× | (96.24%) |
| FY2019 | 1,412× | (93.94%) |
| FY2018 | 23,317× | — |
| FY2017 | 0.0× | — |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Dec 2025 | −142× | — |
| Mar 2025 | −193× | — |
| Dec 2024 | −120× | — |
| Jun 2024 | −59.3× | — |
| 20 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| CELZ Creative Medical Technology Holdings, Inc. | −378× |
| AZTR Azitra, Inc. compare | −9.1× |
| XBIO Xenetic Biosciences, Inc. compare | −0.3× |
| CVKD Cadrenal Therapeutics, Inc. compare | n/m |
| DRMA Dermata Therapeutics, Inc. compare | n/m |
| NCNA NuCana PLC Sponsored ADR compare | n/m |
| PMCB Nuvilex Inc. compare | n/m |
| OSRH OSR Health, Inc. compare | 4.9× |
| ADTX Aditxt, Inc. compare | 73.3× |
| Biotechnology industry median | 9.0× |
| Healthcare sector median | 3.6× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)